Entrectinib
Sign in to save this workspacePrimary targets: TRKA · FDA status: FDA Approved
Selectivity scorecard
KISS
93.69
Gini
0.671
CATDS
0.013
Computed from wild-type kinome inhibition at 1 μM. Gini reproduces the published values within tolerance; KISS and CATDS are computed but pending reconciliation with the paper's reference code.
Polypharmacology radar
Top 20 strongest-inhibited wild-type kinases for Entrectinib. Strongest target: HASPIN at 100.0% inhibition.
Accessible data table
| Rank | Target | Inhibition % | Residual activity % |
|---|---|---|---|
| 1 | HASPIN | 100.0% | 0.0% |
| 2 | TRKB | 99.8% | 0.2% |
| 3 | RET | 99.6% | 0.4% |
| 4 | ROS_ROS1 | 99.3% | 0.7% |
| 5 | TXK | 99.1% | 0.9% |
| 6 | TRKA | 99.0% | 1.0% |
| 7 | JAK2 | 99.0% | 1.0% |
| 8 | TRKC | 98.8% | 1.2% |
| 9 | ALK | 98.8% | 1.2% |
| 10 | TYK2 | 97.9% | 2.1% |
| 11 | IRR_INSRR | 97.5% | 2.5% |
| 12 | ACK1 | 97.3% | 2.7% |
| 13 | TYK1_LTK | 97.3% | 2.7% |
| 14 | HPK1_MAP4K1 | 96.3% | 3.7% |
| 15 | FLT3 | 96.1% | 3.9% |
| 16 | DDR1 | 96.0% | 4.0% |
| 17 | MUSK | 95.9% | 4.1% |
| 18 | FGR | 95.4% | 4.6% |
| 19 | BTK | 95.1% | 4.9% |
| 20 | ARK5_NUAK1 | 93.5% | 6.5% |
Selectivity landscape
Where Entrectinib sits in the 92-drug selectivity landscape (KISS vs Gini). The highlighted point is Entrectinib.
Annotations
Sign in to read and post annotations.
Loading…